Get started
Author

Konstance Nicolopoulos

ORCID: 0000-0001-8165-189X
Observed ORCID: 0000-0001-8165-189X
OpenAlex ID: A5084237040
Association between habitual coffee consumption and multiple disease outcomes: A Mendelian randomisation phenome-wide association study in the UK Biobank
2020 · Konstance Nicolopoulos, Anwar Mulugeta, et al. · Clinical Nutrition · 51
The Clinical Effectiveness of Denosumab (Prolia®) for the Treatment of Osteoporosis in Postmenopausal Women, Compared to Bisphosphonates, Selective Estrogen Receptor Modulators (SERM), and Placebo: A Systematic Review and Network Meta-Analysis
2023 · Magdalena Ruth Moshi, Konstance Nicolopoulos, et al. · Calcified Tissue International · 42
The clinical effectiveness of denosumab (Prolia®) in patients with hormone-sensitive cancer receiving endocrine therapy, compared to bisphosphonates, selective estrogen receptor modulators (SERM), and placebo: a systematic review and network meta-analysis
2023 · Konstance Nicolopoulos, Magdalena Ruth Moshi, et al. · Archives of Osteoporosis · 11
OP52 Treating Osteoporosis In Postmenopausal Women With Denosumab (Prolia®): A Systematic Review And Network Meta-Analysis
2023 · Magdalena Ruth Moshi, Konstance Nicolopoulos, et al. · International Journal of Technology Assessment in Health Care · 1
PDF
Managing Outliers in Australian Surgical Clinical Quality Registries
2026 · Alun Cameron, Konstance Nicolopoulos, et al. · ANZ Journal of Surgery
PDF
OP42 Cost-Utility Analysis Of Axicabtagene Ciloleucel (Yescarta) Versus Standard Care For Relapsed Or Refractory Large B-Cell Lymphoma – Health Payer Perspective
2025 · Danielle Stringer, Ming Min, et al. · International Journal of Technology Assessment in Health Care
PDF
OP70 Treating Patients With Hormone-Sensitive Cancer On Endocrine Therapy With Denosumab (Prolia®): A Systematic Review And Network Meta-Analysis
2023 · Konstance Nicolopoulos, Magdalena Ruth Moshi, et al. · International Journal of Technology Assessment in Health Care
PDF
OP129 A Cost-Utility Analysis Of Denosumab (Prolia®) For Treating Osteoporosis In Postmenopausal Women: A Swiss Healthcare Payer Perspective
2023 · Danielle Stringer, Magdalena Ruth Moshi, et al. · International Journal of Technology Assessment in Health Care
PDF
Works count: 8
Citation count: 105
H-index: 3
I10-index: 3
Year
Topic
Type